Ploquin Anne, Truant Stephanie, Piessen Guillaume, Vuagnat Perrine, Baldini Capucine, Cattan Stephane, Hebbar Mohamed
Department of Medical Oncology, University Hospital, Lille, France
Department of Digestive Surgery and Transplantation, University Hospital, Lille, France.
In Vivo. 2017 Jul-Aug;31(4):731-735. doi: 10.21873/invivo.11122.
Prognosis of patients with locally advanced or metastatic pancreatic adenocarcinoma is poor. In this study, we assessed the predictive value of easily available baseline factors for prolonged survival.
We conducted a retrospective study on patients who received gemcitabine between 1999 and 2010 for locally advanced or metastatic pancreatic adenocarcinoma. The primary end-point was the 12-month survival rate.
We included 195 patients. The median age was 62.9 years; the performance status was 0-1 in 80 and 2-3 in 92 patients. The median number of metastatic sites was one. A total of 73 patients (37.4%) were alive 12 months after beginning chemotherapy. In multivariate analysis, no liver metastasis, CA19-9 level <250 IU/ml and localized or locally advanced cancer at diagnosis were good prognostic factors. According to a clinical score based on these features, overall survival was 7.7, 13.5, 19.7 and 21.0 months, respectively (p<0.001).
We identified easily available prognostic factors for prolonged survival in patients treated with gemcitabine.
局部晚期或转移性胰腺腺癌患者的预后较差。在本研究中，我们评估了易于获得的基线因素对延长生存期的预测价值。
我们对1999年至2010年间接受吉西他滨治疗的局部晚期或转移性胰腺腺癌患者进行了一项回顾性研究。主要终点是12个月生存率。
我们纳入了195例患者。中位年龄为62.9岁；80例患者的体能状态为0 - 1，92例患者为2 - 3。转移部位的中位数为1个。开始化疗后12个月，共有73例患者（37.4%）存活。在多变量分析中，无肝转移、CA19 - 9水平<250 IU/ml以及诊断时为局限性或局部晚期癌症是良好的预后因素。根据基于这些特征的临床评分，总生存期分别为7.7、13.5、19.7和21.0个月（p<0.001）。
我们确定了接受吉西他滨治疗患者延长生存期的易于获得的预后因素。
